Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo

BACKGROUND: Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellular matrix...

Descripción completa

Detalles Bibliográficos
Autores principales: Reker, Ditte, Kjelgaard-Petersen, Cecilie F., Siebuhr, Anne Sofie, Michaelis, Martin, Gigout, Anne, Karsdal, Morten A., Ladel, Christoph, Bay-Jensen, Anne C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727954/
https://www.ncbi.nlm.nih.gov/pubmed/29233174
http://dx.doi.org/10.1186/s12967-017-1356-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727954/
https://www.ncbi.nlm.nih.gov/pubmed/29233174
http://dx.doi.org/10.1186/s12967-017-1356-8

Ejemplares similares